Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.

@article{Tamura2011PhaseIF,
  title={Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.},
  author={Shigeyuki Tamura and Kazumasa Fujitani and Yutaka Kimura and Takeshi Tsuji and Jin Matsuyama and Shohei Iijima and Hiroshi Imamura and Kentaro Inoue and Kenji Kobayashi and Yukinori Kurokawa and Hiroshi Furukawa},
  journal={Oncology},
  year={2011},
  volume={80 5-6},
  pages={296-300}
}
OBJECTIVE The aim of this prospective study was to evaluate the feasibility and safety of adjuvant S-1 plus docetaxel in patients with stage III gastric cancer. METHODS We enrolled 53 patients with pathological stage III gastric cancer who underwent D2 gastrectomy. They received oral S-1 (80 mg/m(2)/day) administration for 2 consecutive weeks and… CONTINUE READING